Articles by A. Nair - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by A. Nair

A. Nair

A. Nair is a freelance writer based in Mumbai, India.

Report from India
February 2, 2012

The Asian nation is strategizing to take the lead over its regional competitors in pharmaceutical exports.

Report from India
October 2, 2011

In an effort to balance bilateral trade, India is urging China to increase Indian pharmaceutical imports.

Report from India
June 2, 2011

India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.

Report from India
February 2, 2011

As biologic-drug patents move toward expiration in the US, Indian firms with experience in the follow-on biologics arena are eager to partner with global manufacturers and secure their place in the growing biosimilars market.

Report from India
November 2, 2010

IP rights and levels of innovation have opened a bit of controversy regarding decisions being made by Indian courts and legislators.

Report from India
July 2, 2010

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

Report from India
March 2, 2010

Could President Obama's tax reform, which is targeted at reducing outsourcing, endanger India's contract-services industry?

In the Field: Report from India
December 2, 2009

Multinational firms and governments around the world are flocking to India for R&D partnerships.

Report From: India
October 2, 2009

Pharmaceutical companies in India have had a hold on the biotechnology sector for many years, and they're not about to let the follow-on biologics market pass them by.


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here